These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Matikainen MP; Schleutker J; Mörsky P; Kallioniemi OP; Tammela TL Clin Cancer Res; 1999 Jun; 5(6):1275-9. PubMed ID: 10389909 [TBL] [Abstract][Full Text] [Related]
3. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831 [TBL] [Abstract][Full Text] [Related]
4. [Adenocarcinoma of the prostate]. Dvorácek J Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503 [TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Roobol MJ; Kranse R; de Koning HJ; Schröder FH Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478 [TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985 [TBL] [Abstract][Full Text] [Related]
7. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Roobol MJ; Roobol DW; Schröder FH Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum markers for prostate cancer. Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759 [TBL] [Abstract][Full Text] [Related]
9. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia. Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237 [TBL] [Abstract][Full Text] [Related]
10. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine]. Bourel M; Ardaillou R; Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060 [TBL] [Abstract][Full Text] [Related]
11. Should prostate-specific antigen screening be offered to asymptomatic men? van Vugt HA; Bangma CH; Roobol MJ Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694 [TBL] [Abstract][Full Text] [Related]
12. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy? Naya Y; Ayala AG; Tamboli P; Babaian RJ Urology; 2004 Mar; 63(3):503-8. PubMed ID: 15028446 [TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481 [TBL] [Abstract][Full Text] [Related]
14. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era. Tonita JM; Skarsgard D; Muhajarine N Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Vutuc C; Schernhammer ES; Haidinger G; Waldhör T Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872 [TBL] [Abstract][Full Text] [Related]
16. Comparative study on the prevalence of clinically detectable prostate cancer in patients with and without bladder cancer. Kurokawa K; Ito K; Yamamoto T; Takechi H; Miyamoto S; Suzuki K; Yamanaka H Urology; 2004 Feb; 63(2):268-72. PubMed ID: 14972469 [TBL] [Abstract][Full Text] [Related]
17. New circulating biomarkers for prostate cancer. Bensalah K; Lotan Y; Karam JA; Shariat SF Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918 [TBL] [Abstract][Full Text] [Related]
18. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754 [TBL] [Abstract][Full Text] [Related]
19. Prostate cancer update: 2005. Ryan CJ; Small EJ Curr Opin Oncol; 2006 May; 18(3):284-8. PubMed ID: 16552242 [TBL] [Abstract][Full Text] [Related]
20. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]